"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 4 | 2 | 6 |
| 1998 | 3 | 1 | 4 |
| 1999 | 5 | 1 | 6 |
| 2000 | 3 | 1 | 4 |
| 2001 | 5 | 0 | 5 |
| 2002 | 8 | 4 | 12 |
| 2003 | 4 | 2 | 6 |
| 2004 | 6 | 3 | 9 |
| 2005 | 8 | 1 | 9 |
| 2006 | 11 | 6 | 17 |
| 2007 | 9 | 3 | 12 |
| 2008 | 12 | 3 | 15 |
| 2009 | 15 | 5 | 20 |
| 2010 | 16 | 8 | 24 |
| 2011 | 20 | 11 | 31 |
| 2012 | 12 | 6 | 18 |
| 2013 | 22 | 9 | 31 |
| 2014 | 21 | 5 | 26 |
| 2015 | 26 | 9 | 35 |
| 2016 | 30 | 7 | 37 |
| 2017 | 19 | 7 | 26 |
| 2018 | 24 | 8 | 32 |
| 2019 | 20 | 5 | 25 |
| 2020 | 19 | 6 | 25 |
| 2021 | 19 | 4 | 23 |
| 2022 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Halogenated Flavonoid Derivatives Display Antiangiogenic Activity. Molecules. 2022 Jul 25; 27(15).
-
Tolypocladamides A-G: Cytotoxic Peptaibols from Tolypocladium inflatum. J Nat Prod. 2022 06 24; 85(6):1603-1616.
-
Synthesis and Evaluation of Functionalized Aryl and Biaryl Isothiocyanates against Human MCF-7 Cells. ChemMedChem. 2022 07 19; 17(14):e202200250.
-
Synthesis of 3-N-/O-/S-methyl-imidazo[1,2-a] pyridine derivatives for caspase-3 mediated apoptosis induced anticancer activity. Bioorg Chem. 2022 08; 125:105882.
-
Nanomedicine as a magic bullet for combating lymphoma. J Control Release. 2022 07; 347:211-236.
-
Crystal structure of the middle and C-terminal domains of Hsp90a labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target. Acta Crystallogr D Struct Biol. 2022 May 01; 78(Pt 5):571-585.
-
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates. Oncotarget. 2022; 13:553-575.
-
Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis. Environ Toxicol. 2022 Jun; 37(6):1445-1457.
-
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. Bosn J Basic Med Sci. 2022 Feb 01; 22(1):14-21.
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.